Aditi Sapre - Concepedia

Concepedia

Author

Aditi Sapre

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

A Sapre, A. Sapre, Aditi Sapre, Ashutosh M Sapre, Sapre, Aditi

34

Publications

1.5K

Citations

15

H-Index

29

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Louisville Metabolic and Atherosclerosis Research Center University of Bonn Baylor College of Medicine National Clinical Research

AS

About

Aditi Sapre is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1K
2	Public Health	2	2	206
3	Health Sciences	1	1	87
4	Diabetes	1	1	99
5	Epidemiology	1	1	30

Aditi Sapre

×

16

Publications

1.5K

Citations

15

H-Index

	Year	Citations
Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia Saskia de Jongh, Leiv Ose, Tamás Szamosi, Circulation	2002	308
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients Daniel M. Bloomfield, Gary L. Carlson, Aditi Sapre, American Heart Journal Lipid DisorderCardiovascular DiseaseMedicineDyslipidemic PatientsCardiovascular Pharmacology	2008	242
Efficacy and Safety of Ezetimibe Coadministered With Simvastatin in Patients With Primary Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled Trial Anne C. Goldberg, Aditi Sapre, Ji Liu, Mayo Clinic Proceedings Primary HypercholesterolemiaLipid DisorderCardiovascular DiseaseMedicinePlacebo-controlled Trial	2004	193
A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia Harold Bays, Leiv Ose, Neil J. Fraser, Clinical Therapeutics Metabolic SyndromeThrombosisPrimary HypercholesterolemiaNon-pharmacological InterventionLipid Disorder	2004	176
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study John J.P. Kastelein, Joost Besseling, Sukrut Shah, The Lancet Metabolic SyndromeLipid DisorderHeterozygous Familial HypercholesterolaemiaCardiovascular DiseaseDiabetes	2015	99
Etoricoxib in acute pain associated with dental surgery: A randomized, double-blind, placebo- and active comparator-controlled dose-ranging study Kerstin Malmström, Aditi Sapre, Heather Couglin, Clinical Therapeutics Pain TherapyInterventional Pain MedicineHealth SciencesAcute PainPain Medicine	2004	87
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial Heather Platt, Tosin Omole, José F. Cardona, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccinologyPhase 1/2Immunology	2022	79
Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men Thomas Sudhop, Michaël Reber, Diane L. Tribble, Journal of Lipid Research	2009	67
Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study Dieter Lütjohann, Klaus von Bergmann, Waheeda Sirah, International Journal of Clinical Practice Drug SafetyTherapeutic Drug MonitoringHomozygous SitosterolemiaMaximal ReductionsPlasma Sitosterol	2008	66
Safety of extended-release niacin/laropiprant in patients with dyslipidemia James M. McKenney, Harold Bays, Michael J. Koren, Journal of clinical lipidology Extended-release Niacin/laropiprantLipid DisorderCardiovascular DiseaseMedicineHyperlipidemia	2010	33

Page 1